NORTH DALLAS, Texas and PLANO, Texas, March 10 /PRNewswire/ -- Tired of frequent Botox injection visits? GFX might be the long-term wrinkle solution for you!
Newly-FDA approved GFX (Glabella Furrow Relaxation) recently arrived in North Texas and is already making waves -- radiofrequency waves, to be exact -- in select aesthetic centers and cosmetic surgery offices. GFX is a unique technological advancement in facial rejuvenation that offers long-term relaxation of overactive 'frown' muscles; a proposition likely to thrill many long-time Botox users, but one that targets the Botox(R) empire for a kill-shot where it would hurt the most ... right between the eyebrows.
Botox(R) muscle-relaxing injection results typically last from 3 to 4 months on average, while the results of one in-office GFX (sometimes called 'No-tox') treatment averages 18 months or longer. According to Jeffrey Adelglass, M.D., F.A.C.S., a popular North Dallas area cosmetic surgeon who has had plenty of experience working with a variety of cosmetic injectables, treatment of the glabella area alone constitutes approximately 65% -- the lion's share -- of his Botox injections. While his GFX patients might still receive periodic Botox(R) injections in other forehead areas (GFX is currently only FDA-approved for the glabella), sometimes keeping the glabella relaxed can, over time, soften wrinkles in other forehead areas, as well. An observed effect of the treatment has been that eyebrows gradually tend to become more elevated and horizontal forehead lines reduced, potentially eliminating the need for elective surgery or neurotoxin injections entirely for some aesthetic patients.
How does GFX work? This minimally-invasive, in-office procedure
utilizes a specified dose of radiofrequency (RF) thermal energy, delivered
through an insulated bipolar needle inserted near the eyebrows, on either
side of the forehead. First, the doctor delivers a stimulating pulse
through the needle to
|SOURCE SKINTASTIC Medical and Surgical Rejuvenation Center|
Copyright©2008 PR Newswire.
All rights reserved